Melanotan II
A synthetic analog of alpha-melanocyte-stimulating hormone; not FDA-approved.
What it is
Melanotan II is a synthetic analog of the hormone that drives melanin production. It emerged from legitimate university research into UV-free tanning, but development as a drug stopped — and what circulates today is an unregulated injectable sold through gray-market channels.
Health agencies in several countries have issued explicit warnings against it, citing reported adverse events and the risks of unregulated injectables. Its cousin afamelanotide is an approved drug for a rare photosensitivity disorder — a useful contrast between a molecule that finished the regulatory journey and one that didn't.
What researchers have actually studied it for
Skin pigmentation and, in early research, erectile function; development stopped short of approval and health agencies have warned against its use.
How it works
A potent, non-selective melanocortin agonist: it drives melanocytes to produce melanin (the tan), while its off-target receptor activity produces the appetite suppression and sexual effects that made its pharmacology famous — non-selectivity is precisely why it was never developable as a tanning drug.
Where it came from
The same University of Arizona program that led to bremelanotide created melanotan II in the early 1990s, aiming at sunless tanning for skin-cancer prevention. Licensing efforts fizzled; the synthesis escaped into gray-market labs in the 2000s, and 'tan-jab' warnings from health agencies have followed it since.
What the research record actually contains
- Small early human studies confirming pigmentation and the famous side-effect profile.
- No completed development program; no controlled safety characterization.
- A parallel legitimate molecule — afamelanotide (Scenesse) — approved for erythropoietic protoporphyria, showing what the finished path looks like.
What's known about risks
Reported concerns include nausea, flushing, blood-pressure effects, appetite suppression, spontaneous erections — and the dermatological one clinicians emphasize: darkening and changing moles, with case reports of atypical lesions prompting biopsies. Unregulated vials and home injection multiply every risk.
Where it stands legally
Unapproved in the US, UK, EU and Australia; multiple regulators have acted against sellers. Persistently available anyway — as an unregulated injectable with none of the protections its buyers assume.
Worth asking a licensed provider
- 1.Given my skin type and mole history, what surveillance would even be needed if I'd used this?
- 2.What legitimate photoprotection strategies fit my situation?
- 3.Am I confusing this with the approved drug afamelanotide, and does that pathway apply to me?